Bispecific CD19/22 CAR T cells

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameBispecific CD19/22 CAR T cells
Drug Alias Namebispecific CD19/22 CAR T cells (优卡迪)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, Non-HodgkinLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLymphoma

Other Information

ATC CodeN/A
Related LinksN/A